The expression of immunoglobulin-based artificial receptors in normal T lymphocytes provides a means to target lymphocytes to cell surface antigens independently of major histocompatibility complex restriction. Such artificial receptors have been previously shown to confer antigen-specific tumoricidal properties in murine T cells. We constructed a novel z chain fusion receptor ( ) specific for prostate-specific membrane antigen PSMA termed Pz-1. PSMA is a cell-surface glycoprotein expressed on prostate cancer cells and the neovascular endothelium of multiple carcinomas. We show that primary T cells harvested from five of five patients with different stages of prostate cancer and transduced with the Pz-1 receptor readily lyse prostate cancer cells. Having established a culture system using fibroblasts that express PSMA, we next show that T cells expressing the Pz-1 receptor release cytokines in response to cell-bound PSMA. Furthermore, we show that the cytokine release is greatly augmented by B7.1-mediated costimulation. Thus, our findings support the feasibility of adoptive cell therapy by using genetically engineered T cells in prostate cancer patients and suggest that both CD4
Introduction
The infusion of T lymphocytes as a therapeutic modality against cancer is based on the premise that tumor-reactive lymphocytes can be expanded ex vivo and retain their antitumoral functions upon reinfusion in vivo. While autologous adoptive cell therapies have shown some beneficial [ ] effects in cancer patients with solid tumors 1 , they are limited by several biological obstacles that include difficulties in generating tumor-specific lymphocytes and the likely occurrence of anergy and / or cell death facing the infused [ ] lymphocytes 2,3 . In principle, these shortcomings could be in part remedied by genetically programming the T cells to [ ] recognize tumor cells 4 and to survive in a proapoptotic [ ] ( ) environment 5 . Artificial T-cell receptors TCR that incorporate the antigen-specific moiety of an immunoglobulin, ( ) expressed as a single chain antibody scFv , provide a means to target antigens independently of major histocom-( ) patibility complex MHC expression. Such receptors are therefore expected to target T cells to tumor cells irrespective of the patient's MHC haplotype and of MHC expression by tumor cells. The targeted antigen must be a cell surface antigen, ideally absent from normal tissues or at least less accessible therein. To elicit T-cell functions, recognition of antigen must be followed by an activation signal transduced via the receptor's cytoplasmic domain. Artificial TCRs that include the activation domain of the CD3 -associated z chain have been shown to confer tumoricidal properties to [ ] murine T cells 4 . However, their activity in cancer patient lymphocytes has not yet been reported.
We have created an scFv-based z chain fusion receptor, termed Pz-1, that is specific for prostate-specific membrane ( ) antigen PSMA . PSMA is a cell-surface glycoprotein expressed on prostate epithelial cells whose expression is [ ] increased in advanced prostate cancer 6 -8 . PSMA is thus an attractive target molecule for immunotherapy in patients with advanced prostate cancer, for which there is no effective treatment. Moreover, PSMA is found in the neovasculature of numerous solid tumors including renal cell, urothelial, colon and breast carcinomas as well as melanoma and ([ ] ) sarcoma 8 ; Chang et al., manuscript submitted , and thus lymphocyte targeting to PSMA is potentially of broader use. Taking advantage of highly efficient gene transfer in human [ ] primary T cells 9 , we therefore examined the function of z chain fusion receptors in T cells from prostate cancer paAbbreviations: CTL, cytotoxic T lymphocyte; FITC, fluorescein isothiocyanate; IFN, interferon; IL-2, interleukin-2; MHC, major histocompatibility complex.; NTP, truncated form of the human low affinity nerve growth factor receptor; PBL, peripheral blood lymphocyte; PE, phycoerythrin; PSMA, prostate-specific membrane antigen; Pz-1, PSMA-specific J591-z chain fusion receptor; scFv, single chain antibody ( ) fragment variable ; TCR, T-cell receptor. tients. We demonstrate that Pz-1 is capable of directing ( ) peripheral blood lymphocytes PBL to specifically recognize and lyse prostate cancer cells expressing PSMA. We show that cytotoxicity against PSMA-positive target cells was obtained in the PBL of 5 out of 5 patients. Furthermore, we assessed the cytokine response of T cells transduced with Pz-1 upon contact with PSMA-positive cells and examined whether CD28-mediated costimulation synergized with Pz-1 signaling to augment the cytokine release of PSMA-specific human T cells. These observations have important implications for the generation and use of genetically engineered autologous lymphocytes to treat cancer. 
Materials and Methods

Cell
PBL Cocultivation
For cocultivation with fibroblasts, 10 5 NIH3T3 cells per well were irradiated and cultured in AIM-V serum free media ( ) Gibco-BRL, Gaithersburg, MD supplemented with 5% DCS. The following day, 10 6 T cells per well were added. Supernatants were analyzed at 24, 48, and 72 hours after ( ) start of the cocultivation for IL-2 and interferon IFN -g with ( ) ELISA kits Genzyme, Cambridge, MA .
Cytotoxicity Assays ( ) Cytotoxic T lymphocyte CTL assays were performed 4 to 14 days after PBL transduction. Transduced PBL were ( ) incubated for 4 hours at different effector to target E:T ratios with 10 4 chromium 51 -labeled target cells at 378. Triplicate supernatants were counted using an automated gamma counter. Percent specific 51 Cr release was calcu-( 51 ) ( lated by Cr releasey spontaneous release / maximum 51 ) Cr releasey spontaneous release = 100.
Results
Pz-1 Transduction and Expression in Human Primary T Lymphocytes
The PSMA specific -z chain chimeric receptor Pz-1 was ( ) cloned into a retroviral vector Figure 1A and transduced in Figure 2A . As shown in Figure 2B , the PBL of all three patients were able to recognize and lyse 51 Cr -labeled LNCaP after transduction with Pz-1 but not NTP. PC-3, a human prostate cancer cell line normally negative for PSMA, and EL-4, a murine thymoma, were transduced with a ( retrovirus encoding PSMA Latouche et al., unpublished ) observations . PSMA expression was confirmed by Western Tables 1 and 2 were transduced with either Pz -1 or NTP 9 . Transduced PBL were used in CTL assays with LNCaP target cells. Percentage of specific lysis is represented on the Y axis, effector to target ratio on the X axis. Figure 3A shows Figure 2A .
T-cell populations transduced with Pz-1 but not NTP lysed both human and murine PSMA q target cells very ( ) effectively Figure 3B and C . The same results were achieved with Pz-1 -transduced PBL from two other patients ( with advanced, hormone-refractory prostate cancer data ) not shown . Cytotoxicity was PSMA-specific, as Pz-1 -transduced T cells did not kill PSMA-negative PC-3 or EL-4 cells any more than NTP-transduced lymphocytes. Back- ground cytotoxicity levels varied on the human target cell lines but remained very low on the murine cells, suggesting that the allogeneic disparity between patient T cells and human target cell lines accounted for the higher background levels. The level of cytolytic activity did not closely correlate with the transduction rate achieved or the percentage of CD8 q in each case. Thus, elevated PSMA-specific cytotoxicity was obtained in Pz-1 -transduced T cells in five of five prostate cancer patients, independent of their age and clinical stage of disease.
Pz-1 Signaling Causes Cytokine Secretion by Transduced PBL To further assess the response of Pz-1 -transduced primary T cells to PSMA, we investigated whether Pz-1 q PBL could release cytokines upon engagement with cell-bound PSMA. We established a cocultivation system in which transduced PBL are cultured on a monolayer of NIH3T3 fibroblasts engineered to express PSMA. NIH3T3 cells were transduced with retrovirus encoding PSMA, human B7.1 ( ) CD80 , or both PSMA and B7.1. Figure 4A ( ) any feeder layer. However, IL-2 and IFN-g data not shown secretion were strongly potentiated in the presence of both PSMA and B7.1, resulting in 10 -fold higher IL-2 release ( ) after 24 hours Figure 4B . Thus, cytokine secretion confirmed that B7.1-mediated signaling provided functional costimulation in Pz-1 -transduced T cells stimulated by cell-bound antigen, suggesting that Pz-1 signaling synergized with B7.1-mediated costimulation. During the cocultivation, Pz-1 q PBL destroyed PSMA q monolayers within 48
hours, whereas the PSMA -B7.1 q monolayer remained intact during the entire 4-day cocultivation.
Discussion
Our results have several implications for the generation, expansion, and therapeutic use of T lymphocytes genetically targeted to a defined antigen. Using highly efficient [ ] retroviral-mediated gene transfer 9 , we were able to investigate Pz-1 function in human primary CD4 q and CD8 q T cells. First, we show that T cells of cancer patients can be genetically directed to recognize and lyse tumor cells that express the cell-surface antigen PSMA. The demonstration that an antigen-specific z chain fusion receptor is functional in cancer patient lymphocytes is an important step toward the implementation of adoptive cell therapies based on the genetic alteration of autologous polyclonal PBL. Indeed, defective TCR signaling has been observed in chronic tu-[ ] mor bearing mice and cancer patients 10,11 . However, we found that the Pz-1 receptor was functional in T cells in five of five cancer patients, including three with advanced disease. These results suggest that T cell activation defects are either uncommon or bypassed by genetically modifying T cells with z chain fusion receptors. These results, therefore, alleviate our earlier concerns that findings in normal T cells might not extend to cancer patient cells.
All reports to date describing z chain fusions have focused on the antigen-specific killing imparted by the recep-( [ ] ) tor reviewed in Ref. 4 . However, the ability of z chain receptors to provide antigen specific helper functions has not been examined. We show that Pz-1 specifically elicited cytokine release when culturing the transduced lymphocytes on PSMA q murine fibroblasts. This result indicates that the Pz-1 receptor provided a sufficient signal to trigger T-cell activation. However, the cytokine secretion was rela-( ) tively weak and not sustained Figure 4B . We therefore investigated whether providing costimulation to the transduced lymphocytes would increase their cytokine response. Indeed, whereas z chain signaling provides a powerful activation signal after engagement of the physiologic TCR, full T-cell activation typically requires a costimulatory signal [ ] 12 . Costimulation could act by amplifying the activation signal or offsetting putative proapoptotic signaling by the Pz-1 receptor.
On a practical level, our results also suggest a strategy to expand cells expressing an artificial TCR. In vitro, fibroblast monolayers that express antigen and B7 are very effective as shown here. Different approaches can be envisaged to provide costimulation in vivo. One is to express B7. 
